A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.
Marginal Zone Lymphoma
DRUG: Ibrutinib|DRUG: Rituximab|OTHER: Placebo
complete response, per the RECIL criteria, 30 months after randomization
The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.